Celaxia

Celaxia is a biopharmaceutical company dedicated to the development of novel treatments for autoimmune and gastrointestinal disorders, specifically focusing on Celiac disease. The company's lead asset, CX-011, is a proprietary oral formulation of calcitonin that aims to provide a non-invasive therapeutic option for patients who remain symptomatic despite a gluten-free diet. Celaxia was acquired by Glenmark Pharmaceuticals in 2020 to bolster Glenmark's specialty pipeline in the immunology and gastroenterology space. The company's approach centers on repurposing established biologics into oral delivery formats to improve patient compliance and outcomes. By leveraging specialized drug delivery technology, Celaxia addresses the significant unmet medical need in the management of gluten-mediated inflammation.